InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
58,108.71
(
2.58%
)
Post# of 320
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

mlkrborn

Send PM Follow Ignore
Followers 40
Posts 7682
Boards Moderated 1
Alias Born 01/04/2006

mlkrborn

Re: None

Thursday, 01/19/2012 7:45:58 PM

Thursday, January 19, 2012 7:45:58 PM

Post# of 320
Biovest prepares for EU Regulatory Meetings; SME status granted providing European regulatory benefits for BiovaxID personalized lymphoma vaccine (BVTI) 0.39 : Co announced that the European Medicines Agency has granted Small and Medium Sized Enterprise status to Biovest. With EMA SME status confirmed, Biovest will be provided with certain administrative and economic benefits related to the EU regulatory process for the Company's BiovaxID personalized lymphoma vaccine targeting the treatment of certain B-cell subtypes of non-Hodgkin's lymphoma.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up